Proactive Investors - Run By Investors For Investors

Latest data shows potential of Summit Therapeutics' DDS-04 antibiotic to treat pneumonia and sepsis

DDS-04 has now shown its potential to treat Enterobacteriaceae infections in all three key infection sites: urinary tract, bloodstream and lung
bacteria
The world desperately needs new antibiotics with resistance on the rise

Summit Therapeutics PLC (LON:SUMM) has shown that its next generation of antibiotics have the potential to treat potentially deadly infections such as pneumonia and sepsis.

AIM-quoted Summit, which is also listed on the Nasdaq in New York, tested compounds from its DDS-04 series on mice which had been infected with the two conditions.

READ: Summit in line to receive up to US$64mln in funding from US government

The DDS-04 compound cured the mice with sepsis, while it ‘significantly reduced’ the bacterial burden in the lungs in those with pneumonia.

The data build on previous preclinical research in urinary tract infections and suggest that DDS-04 has potential to treat Enterobacteriaceae infections in all three key infection sites: urinary tract, bloodstream and lung.

It is the latter two where there is the greatest unmet patient need, Summit said.

No new antibiotics this century

“There is a great need to advance truly differentiated treatments for Gram-negative bacteria, where there have been no new classes of antibiotics discovered since the last century,” said Summit’s president of R&D, David Roblin.

“In particular, the rise of untreatable and hard to treat Enterobacteriaceae infections is a frightening prospect.

“DDS-04 aligns with our strategy of targeting pathogenic bacteria and seeking to preserve patients’ good bacteria known to play an important role in overall patient health.”

In early afternoon trading, Summitt shares gqained 3.2% at 24.50p.

 -- Updates share price -- 

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

blood
June 21 2019
Belgium-based company’s Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect ovarian disease endometriosis
lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
scientist in laboratory
May 24 2019
Here we take a closer look at healthcare investor NetScientific PLC (LON:NSCI)

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use